JP2008156256A - Oral administration composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To elucidate a means for further improving prophylactic or ameliorating effects on arthrosis and arthritis and to provide an oral administration composition useful for prophylaxis or amelioration of the arthrosis and arthritis by applying the means. <P>SOLUTION: The oral administration composition is obtained by including (1) an extract from the following plant: (plant) Fuscoporia obliqua of the family Polyporaceae, Rhodiola rosea L. of the family Crassulaceae, Eucommia ulmoides of the family Araliaceae, Isodon japonicus Hara of the family Labiatae, Mallotus japonicus Mueller-Arg of the family Euphorbiaceae, Melilotus officinalis of the family Leguminosae, Echinacea pallida of the family Compositae, Crataegus cuneata of the family Rosaceae, Eucommia ulmoides of the family Eucommiaceae, brown algae, green algae or red algae, (2) an alkaline earth metal salt and (3) glucosamine which may be acetylated and/or a salt thereof in the oral administration composition for prophylaxis or amelioration of the arthritis and arthrosis. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to an oral administration composition suitable for foods and the like.

  Due to the tremendous growth in life expectancy in recent years, diseases that have not been regarded as important so far have come to attract attention because they greatly affect the quality of life of the elderly. Such diseases have a major impact on body skeleton-related inflammation such as arthritis and arthritis, body skeletal abnormalities such as osteoporosis, and enjoyment activities such as eating habits and sex life, which greatly inhibit the freedom of action of elderly people. Examples thereof include metabolic disorders such as hyperlipidemia and diabetes. Among these, body skeleton-related inflammations such as arthritis and arthritis, and body skeletal abnormalities such as osteoporosis, which limit actions such as going out to affect the mental health of the elderly, are important countermeasure issues, Body skeleton-related inflammation such as arthritis and arthropathy, which are likely to be dealt with, can be said to be an important coping issue. That is, it can be said that development of a means for preventing or improving arthritis / arthropathy is demanded in order to improve quality of life.

  The treatment usually performed for such arthritis / arthropathy is administration of an anti-inflammatory agent such as diclofenac sodium, aceclofenac, indomethacin (see, for example, Patent Document 1), and oral administration of the anti-inflammatory agent. In many cases, it was difficult to raise the concentration of anti-inflammatory drugs in the joints, and it often caused side effects such as damaging the stomach. In addition, local administration of an anti-inflammatory agent has low reachability to the inflamed site, and various studies have been made on improving reachability (see, for example, Patent Document 2), but such a technique is sufficient. The amount has not been reached.

  Regarding arthritis and arthropathy, the bone mass that constitutes the joint decreases due to a decrease in bone mass over time, deforms and stimulates surrounding nerves, causing pain and compressing surrounding tissues It is said that there are cases where this is partly caused by inflammation. For this reason, it is already known that supplementing calcium and maintaining bone mass can maintain bone strength, suppress deformation, and thus prevent the onset and seriousness of arthritis and arthropathy (for example, However, when this effect is examined in detail, it has been found that the effect on arthritis is low for the effect on bone, but the cause is unknown. It is. For arthritis / arthropathy, a method of preventing or aggravating symptoms by administration of acetylated glucosamine has been used. This is because one of the causes of arthritis and arthropathy is that the biosynthesis of glucosamine, which may be acetylated, does not catch up with the degradation and is insufficient. It is said that arthritis / arthropathy can be improved by administration and supplementation (see, for example, Patent Document 6, Patent Document 7, and Patent Document 8). However, there is a case where arthritis / arthropathy is not improved even though the amount of glucosamine which may be acetylated in the living body is increased by administration of glucosamine which may be acetylated. Research was also sought.

  On the other hand, regarding arthritis / arthropathy, it is already known that matrix metalloproteinases (hereinafter sometimes referred to as MMP) are involved. (See, for example, Patent Document 9 and Patent Document 10) Furthermore, it has not been known at all that a substance having an inhibitory action on MMP activity is contained in an extract of a plant selected from Eucommia ulmoides, brown algae, green algae, and red algae. Furthermore, the composition for oral administration containing the extract, an alkaline earth metal salt such as calcium, and glucosamine, which may be acetylated, is useful for the treatment or prevention of arthritis / arthritis. unknown.

JP 2002-363104 A Japanese translation of PCT publication No. 2002-511057 JP 2001-158736 A Japanese Patent Laid-Open No. 2000-28187 JP 2005-68060 A JP 2002-193811 A JP 2005-501043 gazette JP 2006-83151 A Japanese National Patent Publication No. 10-513168 JP 2005-501091 A

  The present invention has been made under such circumstances, and has clarified means for further improving the prevention / amelioration effect of arthritis / arthritis, and is applied to prevent or improve arthritis / arthritis. It is an object to provide a composition for oral administration.

  In view of such a situation, the present inventors have sought for a useful means for prevention and improvement of arthritis / arthropathy, and as a result of intensive research efforts, the results are: Extracts of plant bodies selected from Lamiaceae toads, Euphorbiaceae, Shrimp, Shrimp, Echinacea parida and Rose hawthorn, Eucommia ulmoides, Brown algae, Green algae, Red algae Coexisting with alkaline earth metal salts such as calcium and glucosamine, which may be acetylated, improves the effect on arthritis, and also has the effect of treating and preventing arthritis / arthritis by inhibiting MMP-13. In order to complete the invention, it has been found to have a significant effect on arthritis and arthritis. Was Tsu. That is, the present invention is as follows.

(1) Prevention or improvement of arthritis / arthropathy containing the following plant extract, 2) alkaline earth metal salt and 3) glucosamine which may be acetylated and / or its salt For oral administration.
(Plant) Fuscoporia obliqua (Fuscoporia obliqua), Rhodiolarosea L., Eucommia ulmoides, Isodon japonicus Hara, Mudella algae Shrimp shrimp (Mallotus japonicus (Thunb.) Muell. Arg.), Echinacea pallida, Crataegus cuneata, Eucommia ulmoides, brown algae, green algae, red algae 2) The composition for oral administration according to (1), wherein the plant extract has a matrix metalloproteinase 13 inhibitory action of 40% or more in a 0.1% solution.
(3) The oral administration composition according to (1) or (2), wherein the alkaline earth metal is calcium.
(4) The composition for oral administration according to any one of (1) to (3), wherein the alkaline earth metal salt is contained after being complexed with an extract.
(5) The composition for oral administration according to any one of (1) to (4), which is a food.
(6) The composition for oral administration according to any one of (1) to (5), which is produced through the following steps.
(Step 1) Sarcophagaceae, Birchidaceae, Kokekiten, Udonaceae, Ezocogi, Lamiaceae, Pteridocyceae, Acamegasiwa, Leguminosae shrimp, Asteraceae, Echinacea paridae, Rosaceae, Eucommia An extraction solvent is added to a plant body selected from green algae and red algae to produce an extract.
(Step 2) Matrix metalloproteinase 13 activity inhibitory action in a 0.1% solution of the extract is measured, and a material in which inhibition of the matrix metalloproteinase 13 activity is 50% or more is selected as a raw material.
(Step 3) After kneading the aqueous solution of the extract selected as a raw material in Step 2 and an alkaline earth metal salt and removing glucosamine and / or its salt and volatile matter which may be acetylated, Grind to produce a production intermediate.
(Step 4) A preparation is prepared using the production intermediate prepared in Step 3, glucosamine which may be acetylated and / or a salt thereof, and an optional component for preparation.

  According to the present invention, a means for further improving the effect of preventing / ameliorating arthropathy / arthritis is clarified and applied to provide a composition for oral administration useful for the prevention / amelioration of arthropathy / arthritis. it can.

(1) Extract as an essential component of the composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing the following plant extract as an essential component.
(Plant) Fuscoporia obliqua (Fuscoporia obliqua), Rhodiolarosea L., Eucommia ulmoides, Isodon japonicus Hara, Mudella algae Shrimp shrimp (Mallotus japonicus (Thunb.) Muell. Arg.), Echinacea pallida, Crataegus cuneata, Eucommia ulmoides, brown algae, green algae, red algae

  The preparation of the extract may be performed according to a conventional method, and 1 to 100 parts by mass of the solvent is added to 1 part by mass of the plant body, and it is immersed for several days at room temperature, for several hours at a temperature near the boiling point, If desired, the insoluble matter can be removed by filtration, and if desired, the solvent can be removed by distillation under reduced pressure, freeze drying, or the like. Furthermore, these extracts can be fractionally purified by column chromatography, liquid-liquid extraction, or the like. As column chromatography, silica gel column chromatography, ion exchange resins such as “Diaion HP-20”, ODS and the like can be suitably exemplified. Of course, the extract of the present invention includes only a part or all of the plant processed by pulverization.

  Any part of the fungus body can be used for the Sarnococcidae birch, and it is particularly preferably a fruiting body. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  As for the crassulaceae, any part of the whole plant can be used, and the whole plant is particularly preferred. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  The part of the whole family can be used, and the root is particularly preferably a root. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  As for the Lamiaceae toad, any part of the whole plant can be used, and the whole plant is particularly preferred. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  As for Euphorbiaceae, any part of the plant can be used, and bark is particularly preferable. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  Any part of the whole legume can be used for leguminous shrimp, and particularly preferred is the above-ground part. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water-containing ethanol extraction is particularly preferred. The water-containing ethanol is preferably one containing 50 to 80% water by volume.

  Asteraceae Echinacea parida can use any part of the whole plant, particularly preferably the root. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water-containing ethanol extraction is particularly preferred. As hydrous ethanol, what contained 20 to 60% of water by volume percentage is preferable.

  The Rosaceae hawthorn can use any part of the plant body, but is particularly preferably a fruit that is an edible part. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  The plant of Eucommia can use any of leaves, flowers, bushes, bark, tree trunks, and roots, but leaves are preferred. This is because the leaf contains a sufficient effective amount of the active ingredient and is excellent in reproductivity. As a solvent used for preparation of the extract, an aqueous polar solvent is preferable, and specifically, an alcohol such as ethanol and / or water is preferable. Of these, hot water extraction is particularly preferred.

  Preferred examples of brown algae include the Sargassum fuluvellum, Hizikia fusiforme, and Sargassum horneri, and the green algae include E. linza J. Agardh, Prolifera J.Ag.), E.compressa Greville, E.intestinalis Link, E.crinita J.Ag., etc. Preferred examples include Solieriaceae, Meristotheca, and mirin. Of these plants, particularly preferred is the genus Amanda. In addition, as for the closely related plant of red mock, pea mushroom (Sargassum giganteifmum) ： Sargassum ringgoldianum, Sargassum sagamianum, Hagashimoku (Sargassum kjellmanianum), Umitoranoo (Sargassum thunbergii), Sargassum confusum, Isosum (Sargassum hemiphyllum), Sargassum hemiphyllum (Sargassum hemiphyllum) nipponicum), ginsou (Sargassum vulgare), phthaemok (Haragimoku: Sargassum duplicatum), ezononomemok (Sargassum yezoense), and the like, and these plants are also preferred after akamoku.

  Below, the manufacture example of the extract of a plant is shown.

<Production Example 1>
Extraction 1 was obtained as 97 g of amorphous substance by adding 2 L of water to 500 g of the fruit body of the moss of Sarnosidaceae, boiled for 3 hours, extracted by cooling to room temperature, filtered to remove insoluble materials, and freeze-dried. .

<Production Example 2>
By the same procedure as in Production Example 1, 500 g of the whole plant of the diatomaceae koukeiten was treated to obtain Extract 2 as 123 g of amorphous.

<Production Example 3>
By the same procedure as in Production Example 1, 500 g of the sorghum family Ezoukogi was treated to obtain Extract 3 as 22 g of amorphous.

<Production Example 4>
The whole plant of Lamiaceae toad was thoroughly dried, pulverized with a mixer, and finely pulverized with a jet mill to obtain an extract 4 as a powder.

<Production Example 5>
In the same manner as in Production Example 1, 500 g of bark of Euphorbiaceae Akamegawashi was treated to obtain Extract 5 as 68 g of powder.

<Production Example 6>
In the same manner as in Production Example 1, treatment was performed using 500 g of the above-ground part of leguminous shrimp and 2 L of 30% aqueous ethanol solution to obtain Extract 6 as 47 g of amorphous.

<Production Example 7>
In the same manner as in Production Example 1, 500 g of Asteraceae Echinacea parida root and 2 L of 60% ethanol aqueous solution were used to obtain Extract 7 as 78 g of amorphous.

<Production Example 8>
In the same manner as in Production Example 1, 500 g of dried product of Rosaceae hawthorn fruit was treated to obtain 68 g of extract 8 as amorphous.

<Production Example 9>
Add 5 liters of water to 1 kg of eucommia leaves, heat and boil for 2 hours, cool to room temperature, filter to remove insolubles, freeze-dry and extract 314 g of extract 9 as a pale yellow amorphous Obtained.

<Production Example 10>
Add 5000 ml of water to 100 g of dried white millinori of the family Milinaceae, sonicate at 85 ° C. for 10 minutes, soak for 2 hours and 30 minutes, return to room temperature, and centrifuge (10000 g × 10 minutes) insoluble matter. And then lyophilized to obtain 22.5 g of the extract 10 as a pale yellow amorphous.

<Production Example 11>
Siromyrinori was replaced with Akatosakanori, and the same treatment was performed to obtain 15.5 g of extract 11 as a pale yellow amorphous.

<Production Example 12>
Siromyrinnori was replaced with Aotosakanori and treated in the same manner to obtain 9.6 g of extract 12 as a pale yellow amorphous.

<Production Example 13>
Siromilinnori was replaced with green algae aonori and treated in the same manner to obtain 32 g of extract 13 as a pale yellow amorphous.

<Production Example 14>
Siromilinnori was replaced with akanori and treated in the same manner to obtain 21.1 g of extract 14 as a pale yellow amorphous.

<Production Example 15>
Siromilinori was replaced with red willow and treated in the same manner to obtain 19 g of extract 15 as a pale yellow amorphous.

<Production Example 16>
Siromilinori was replaced with Aoyagi nori and treated in the same manner to obtain 13.1 g of extract 16 as a pale yellow amorphous.

<Production Example 17>
Siromilinnori was replaced with Akakaedenori and treated in the same manner to obtain 21 g of extract 17 as a pale yellow amorphous.

<Production Example 18>
Siromilinnori was replaced with Aokaedenori and treated in the same manner to obtain 22.1 g of extract 18 as a pale yellow amorphous.

<Production Example 19>
Add 10000 ml of water to 200 g of red mock, soak for 1 hour at room temperature, take out 5000 ml, centrifuge (10000 g × 10 minutes), freeze-dry this 2500 ml, and obtain extract 19-1 of the crude extract fraction . (Yield: 22.7 g) The remaining 2500 ml was subjected to ultrafiltration using an ultrafiltration membrane with a molecular weight cut off of 50,000, and divided into a fraction with a molecular weight of 50,000 or more and a fraction with a molecular weight of less than 50,000. Extract 19-2 was obtained. The fraction less than 50000 is subjected to ultrafiltration using an ultrafiltration membrane having a molecular weight cut off of 3000, and the permeated fraction and the remaining fraction are freeze-dried to obtain an extract 19-3 having a molecular weight of 3000 to 50000, The extract 19-4 had a molecular weight of less than 3000. The remaining 5000 ml is further immersed for 2 hours and 30 minutes at a temperature of 85 ° C. and treated in the same manner as the water extract. The extract 19-5 of the crude extract, the extract 19-6 having a molecular weight of 50000 or more, and the molecular weight 3000 to 50000 Extract 19-7 and an extract 19-8 having a molecular weight of less than 3000 were obtained.

<Production Example 20>
Siromilinnori of Production Example 10 was replaced with Alame and the same treatment was performed to obtain 44.1 g of Extract 20 as a pale yellow amorphous.

<Production Example 21>
In the same manner as in Example 10 except that the white millet was replaced with buckwheat, and 6.6 g of extract 21 was obtained as a pale yellow amorphous.

  The extract thus obtained has excellent matrix metalloprotease inhibitory activity, in particular, matrix metalloprotease 13 (MMP13) inhibitory action, thereby alleviating arthritis / arthropathy or worsening arthritis / arthropathy. Has the effect of preventing In addition, it enhances calcium absorption, suppresses joint bone loss due to bone resorption in joints, etc., suppresses the development of inflammation from joint deformation, and synergistic action prevents or worsens the onset of arthritis / arthropathy Prevents and improves symptoms. In order to exert such action, these extracts are preferably administered by the oral route by dividing 10 to 10000 mg per day into one or several times. It should be noted at this time that MMP13 inhibitory activity is present at 40% or more in a 0.1% solution of the extract. The inhibitory activity can be measured using an existing kit for measuring MMP13 inhibitory activity, for example, “MMP-13 Colorimetric Assay Kit (AK-412)” sold by Funakoshi Pharmaceutical Co., Ltd. The inhibitory activity is calculated by the formula: (1—reaction rate of protease in the presence of sample / reaction rate of protease in the absence of sample) × 100. When the inhibitory activity of MMP13 is less than 40%, there is a case where the above action is not exhibited.

(2) Alkaline earth metal salt which is an essential component of the composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing an alkaline earth metal salt as an essential component. As the alkaline earth metal constituting the alkaline earth metal salt, for example, calcium and magnesium can be preferably exemplified, and calcium is particularly preferable. These salts may be water-soluble, sparingly water-soluble, or water-insoluble. For example, mineral salts such as hydrochlorides, nitrates, sulfates, carbonates and phosphates. And organic acid salts such as citrate, tartrate, malate and the like. Particularly preferred are phosphates or carbonates. Such components supplement bone calcium that has decreased over time, and have the effect of suppressing the occurrence of inflammation and pain in the tissues surrounding the bone due to bone deformation. In order to achieve such an effect, the alkaline earth metal salt is preferably administered by the oral route by dividing 10 to 10000 mg per day into one or several times. It is preferred that this amount be formulated in a dose that can be ingested. Moreover, it is preferable that this intake is 0.1 to 1000 times with respect to the mass of the extract which is said essential component, More preferably, it is 1 to 500 times. By taking such a quantitative ratio, the enhancement of MMP13 activity can be suppressed by the MMP13 inhibitory action of the extract.

(3) The glucosamine which may be acetylated which is an essential component of the composition for oral administration of the present invention The composition for oral administration of the present invention contains glucosamine which may be acetylated as an essential component. To do. Glucosamine has already been marketed as a reagent product or as a raw material for food, and such glucosamine can be purchased and used. Preferred examples of the glucosamine base include crustaceans such as shrimps and crabs. The method for acetylating glucosamine may be in accordance with a conventional method. For example, triethylamine or pyridine may be used as a solvent, and acetyl chloride may be reacted in an equal amount or slightly in excess. Acetylated glucosamine can be used by adjusting it in this way, and it is also possible to purchase and use a commercially available reagent or a raw material for food. As such commercially available products, for example, the product name “natural glucosamine” which is glucosamine and the product name “Marine Sweet” which is N-acetylglucosamine (both sold by Yaizu Suisan Chemical Co., Ltd.) can be preferably exemplified.

  Such a component has an action of increasing degradation due to arthritis / arthropathy, etc., supplementing the deficient in vivo glucosamine, alleviating the symptoms of arthritis / arthropathy, and preventing further deterioration. In order to express such an action, it is preferable to administer glucosamine or acetylglucosamine by oral route by dividing 10 to 10000 mg per day once or several times. Moreover, it is preferable that this intake is 0.1 to 1000 times with respect to the mass of the extract which is the said essential component, More preferably, it is 1 to 500 times. By taking such a quantitative ratio, enhancement of MMP13 activity can be suppressed by the MMP13 inhibitory action of the extract.

(3) Orally administered composition of the present invention The orally administered composition of the present invention is characterized by containing the above essential components and being arthritic / arthritic. The oral administration composition of the present invention is not particularly limited as long as it has the characteristics of oral administration, and examples thereof include oral administration pharmaceutical compositions, foods, and drinks. Among these, foods are particularly preferable, and foods such as foods for specific health expected to have a specific function are particularly preferable. In addition to the essential components described above, the oral administration composition of the present invention can contain optional components usually used in food compositions. Examples of optional ingredients for the formulation include excipients such as lactose, dextrin and cyclodextrin, disintegrants such as starch and cellulose, binders such as hydroxypropylcellulose and gum arabic, and emulsification such as pectin and lecithin. -Dispersants, flavoring agents such as sucrose, honey and maltose, and coating agents such as shellac and gelatin can be suitably exemplified. The oral administration composition of the present invention can be produced by processing such essential components and optional components into tablets, powders, granules, confectionery and the like according to a conventional method.

  In the following, the present invention will be described in more detail, but it goes without saying that the present invention is not limited only to such examples.

<Reference example>
It was investigated whether or not the extracts 1 to 21 produced in the production examples could be used as essential components of the present invention using MMP-13 inhibitory action as an index. MMP13 inhibitory activity was measured using “MMP-13 Colorimetric Assay Kit (AK-412)” using a 0.1% by weight aqueous solution of each sample (only 0.01% by weight of Extract 1). The results are shown in Table 1 as the inhibition rate (%). From this, it can be seen that, with the exception of a part of the extract 19 extract, all the extracts were 0.1% by mass and the MMP inhibitory activity was 40% or more. Therefore, it was found that any extract other than 19-1, 19-3, 19-4 and 19-8 is suitable as the composition for oral administration of the present invention.

  Using the extract for which MMP-13 activity inhibition was measured in the above Reference Example, a food (tablet), which is the composition for oral administration of the present invention, was prepared according to the following formulation. That is, 50 parts by mass of water is added to 40 parts by mass of component (a), mixed with a crusher for 10 minutes, lyophilized, returned to the crusher, pulverized, and this together with other ingredients. Prepared into “Numeralizer” (Fuji Paudal Co., Ltd.), sprayed with 100 ml of water under stirring with air blowing, granulated, blown with hot air of 40 ° C. for 3 hours, dried, tableted Tablet 1 (100 mg) was obtained. Similarly, Comparative Example 1 in which Extract 19-2 was replaced with Extract 19-3 having 0.1% MMP13 inhibitory activity of 30%, Placebo 1 in which Extract 19-2 was replaced with dextrin, and calcium phosphate as dextrin Similarly, placebo 2 substituted with 1 and placebo 3 substituted with “natural glucosamine” with dextrin were also prepared.

<Test Example 1>
Twenty-five people who suffer from arthritis / arthropathy are selected and divided into five groups of five people, one group includes tablet 1, comparative group 1 includes one group, and placebo 1 includes one group. Gave placebo 2 and placebo 3 to the remaining group, and took 2 tablets in the morning and evening for 60 days. After that, the degree of improvement in arthritis and arthropathy was remarkably improved, obviously improved, and slightly improved Table 3 shows the results of the questionnaires that answered the categories that were hardly improved, unchanged, or deteriorated. From this, it can be seen that the composition for oral administration of the present invention is excellent in the effect of improving arthritis / arthropathy.

  Similarly to tablet 1, according to the following formulation, tablet 2 (food) which is an orally administered composition of the present invention was produced. A person suffering from arthritis / arthropathy took 2 tablets each morning and night for 30 days.

  Similarly to tablet 1, according to the following formulation, tablet 3 (food) which is an orally administered composition of the present invention was produced. A person suffering from arthritis / arthropathy took 2 tablets each morning and night for 30 days.

  The present invention can be applied to foods for improving and preventing arthritis and arthropathy such as health foods.

Claims (6)

1) A plant extract shown below, 2) an alkaline earth metal salt, and 3) glucosamine which may be acetylated and / or a salt thereof, for prevention or improvement of arthritis / arthropathy Orally administered composition.
(Plant) Fuscoporia obliqua (Fuscoporia obliqua), Rhodiolarosea L., Eucommia ulmoides, Isodon japonicus Hara, Mudella algae Shrimp shrimp (Mallotus japonicus (Thunb.) Muell. Arg.), Echinacea pallida, Crataegus cuneata, Eucommia ulmoides, brown algae, green algae, red algae The composition for oral administration according to claim 1, wherein the plant extract has a matrix metalloproteinase 13 inhibitory action of 40% or more in a 0.1% solution. The composition for oral administration according to claim 1 or 2, wherein the alkaline earth metal is calcium. The composition for oral administration according to any one of claims 1 to 3, wherein the alkaline earth metal salt is contained after being complexed with an extract. The composition for oral administration according to any one of claims 1 to 4, wherein the composition is a food. The composition for oral administration according to any one of claims 1 to 5, wherein the composition is manufactured through the following steps.
(Step 1) Sarcophagaceae, Birchidaceae, Kokekiten, Udonaceae, Ezocogi, Lamiaceae, Pteridocyceae, Acamegasiwa, Leguminosae shrimp, Asteraceae, Echinacea paridae, Rosaceae, Eucommia An extraction solvent is added to a plant body selected from green algae and red algae to produce an extract.
(Step 2) Matrix metalloproteinase 13 activity inhibitory action in a 0.1% solution of the extract is measured, and a material in which inhibition of the matrix metalloproteinase 13 activity is 50% or more is selected as a raw material.
(Step 3) After kneading the aqueous solution of the extract selected as a raw material in Step 2 and an alkaline earth metal salt and removing glucosamine and / or its salt and volatile matter which may be acetylated, Grind to produce a production intermediate.
(Step 4) A preparation is prepared using the production intermediate prepared in Step 3, glucosamine which may be acetylated and / or a salt thereof, and an optional component for preparation.